Pentara at CTAD 2026

Nov 16–19, 2026 Boston, MA ~1.7k attendees Website

Pentara takes part in 6 sessions at CTAD 2026 in Boston. Its program centres on modelling the long-term effects of anti-amyloid treatment and on trial data quality. Its work covers continuous versus finite dosing of lecanemab and donanemab, a real-world meta-analysis of ARIA and the sensitivity of digital endpoints.

Organization	CTAD 2026 Attendance
Pentara Millcreek, Utah
pentara.com CROs & trial services Biostatistics company that designs and analyses clinical trials, specialising in Alzheimer's endpoints, disease-progression modelling and data integrity.	Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Continuous vs. Finite Dosing Until Amyloid Plaque Clearance in Early Alzheimer’s Disease: A Horizontal Matching Analysis of Long-Term Clinical Trajectories for Lecanemab and Donanemab (P001) Anti-amyloid and anti-tau therapies Poster Mon Nov 16 – Tue Nov 17 2:00pm Mon – 5:30pm Tue Updated Projections Confirm Long-Term Benefits of Continuous Lecanemab: 10 Years of Treatment Could Delay Moderate Disease by 18.7 Years (P002) Anti-amyloid and anti-tau therapies Talk Tue Nov 17 2:05pm Lecanemab Treatment in Real-World Settings Across Multiple Countries: A Meta-Analysis on ARIA Rates and Safety Profiles in Clinical Practice Anti-amyloid and anti-tau therapies · Real-world data and access Poster Wed Nov 18 7:15am–5:30pm Cost and Time Impact of LucentAD Complete as a Blood-Based Diagnostic Aid for Alzheimer’s Disease: A Model-Based Analysis (P283) Blood and CSF biomarkers · Real-world data and access Poster Thu Nov 19 7:15am–5:00pm The Financial and Societal Impact of Compromised Data Integrity in AD Trials and the Importance of Early Detection and Monitoring (P372) Trial design and endpoints Poster Thu Nov 19 7:15am–5:00pm Maximizing Signal in Early AD: How Digital Assessments Outperform the CDR-SB and ADAS-Cog (P442) Digital assessment and AI · Trial design and endpoints

Organization

CTAD 2026 Attendance

Pentara

Millcreek, Utah

pentara.com

CROs & trial services

Biostatistics company that designs and analyses clinical trials, specialising in Alzheimer's endpoints, disease-progression modelling and data integrity.

Poster

Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue

Continuous vs. Finite Dosing Until Amyloid Plaque Clearance in Early Alzheimer’s Disease: A Horizontal Matching Analysis of Long-Term Clinical Trajectories for Lecanemab and Donanemab (P001)

Anti-amyloid and anti-tau therapies

Poster

Mon Nov 16 – Tue Nov 17
2:00pm Mon – 5:30pm Tue

Updated Projections Confirm Long-Term Benefits of Continuous Lecanemab: 10 Years of Treatment Could Delay Moderate Disease by 18.7 Years (P002)

Anti-amyloid and anti-tau therapies

Talk

Tue Nov 17
2:05pm

Lecanemab Treatment in Real-World Settings Across Multiple Countries: A Meta-Analysis on ARIA Rates and Safety Profiles in Clinical Practice

Anti-amyloid and anti-tau therapies · Real-world data and access

Poster

Wed Nov 18
7:15am–5:30pm

Cost and Time Impact of LucentAD Complete as a Blood-Based Diagnostic Aid for Alzheimer’s Disease: A Model-Based Analysis (P283)

Blood and CSF biomarkers · Real-world data and access

Poster

Thu Nov 19
7:15am–5:00pm

The Financial and Societal Impact of Compromised Data Integrity in AD Trials and the Importance of Early Detection and Monitoring (P372)

Trial design and endpoints

Poster

Thu Nov 19
7:15am–5:00pm

Maximizing Signal in Early AD: How Digital Assessments Outperform the CDR-SB and ADAS-Cog (P442)

Digital assessment and AI · Trial design and endpoints

Instantly find 20 buyers from Pentara

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the CTAD Conference. Organization details are derived from CTAD’s published program, poster list and sponsor page. Submit a correction